Evidence mapPaperPMID 31749613Full record

ArticleInternational journal of chronic obstructive pulmonary disease2019

External Validation Of The Updated ADO Score In COPD Patients From The Birmingham COPD Cohort.

Spencer J Keene, Rachel E Jordan, Frits Me Franssen, Frank de Vries, James Martin, Alice Sitch, Alice Margaret Turner, Andrew P Dickens, David Fitzmaurice, Peymane Adab

Abstract readValidation Study
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Can the ADO Index Be Used as a Predictor of Mortality from COVID-19 in Patients with COPD?International journal of chronic obstructive pulmonary disease · 2024
    Observational
  2. Article
  3. Article
  4. Article
  5. Prediction of Mortality Using Different COPD Risk Assessments - A 12-Year Follow-Up.International journal of chronic obstructive pulmonary disease
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Spencer J KeeneInstitute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0003-0622-6476
Rachel E JordanInstitute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Frits Me FranssenCiro, Horn, the Netherlands.ORCID 0000-0002-1633-6356
Frank de VriesDepartment of Clinical Pharmacy & Toxicology, Maastricht University Medical Center+, Maastricht, the Netherlands.
James MartinInstitute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Alice SitchInstitute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Alice Margaret TurnerInstitute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Andrew P DickensInstitute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0002-7591-8129
David FitzmauriceClinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.
Peymane AdabInstitute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0001-9087-3945

Funding

Department of Health RP-PG-0109-10061
6 · The paper itself

Abstract

Background: Reviews suggest that the ADO score is the most discriminatory prognostic score for predicting mortality among chronic obstructive pulmonary disease (COPD) patients, but a full evaluation and external validation within primary care settings is critical before implementation. Objectives: To validate the ADO score in prevalent and screen-detected primary care COPD cases at 3 years and at shorter time periods. Patients and methods: One thousand eight hundred and ninety-two COPD cases were recruited between 2012 and 2014 from 71 United Kingdom general practices as part of the Birmingham COPD Cohort study. Cases were either on the practice COPD register or screen-detected. We validated the ADO score for predicting 3-year mortality with 1-year and 2-year mortality as secondary endpoints using discrimination (area-under-the-curve (AUC)) and calibration plots. Results: One hundred and fifty-four deaths occurred within 3 years. The ADO score was discriminatory for predicting 3-year mortality (AUC= 0.74; 95% CI: 0.69-0.79). Similar performance was found for 1- (AUC= 0.73; 0.66-0.80) and 2-year mortality (0.72; 0.67-0.76). The ADO score showed reasonable calibration for predicting 3-year mortality (calibration slope 0.95; 0.70-1.19) but over-predicted in cases with higher predicted risks of mortality at 1 (0.79; 0.45-1.13) and 2-year (0.79; 0.57-1.01) mortality. Discussion: The ADO score showed promising discrimination in predicting 3-year mortality in a primary care population including screen-detected cases. It may need to be recalibrated if it is used to provide risk predictions for 1- or 2-year mortality since, in these time-periods, over-prediction was evident, especially in cases with higher predicted mortality risks.

Indexed as

Decision Support TechniquesAdultAgedAged, 80 and overAge FactorsDyspneaEnglandFemaleForced Expiratory VolumeHumansLungMaleMiddle AgedPredictive Value of TestsPrevalencePrimary Health Carechronic obstructivemortalityprognosispulmonary diseasevalidation studies

Identifiers

PMID31749613
PMCPMC6818100

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.